BioAge Labs (BIOA) Asset Utilization Ratio (2025 - 2026)
BioAge Labs' (BIOA) quarterly Asset Utilization Ratio came in at 0.03 in Q2 2026, up 124.67% year-over-year from 0.01 in Q2 2025, and down 12.51% quarter-over-quarter from 0.03 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.03 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 124.67% year-over-year to 0.03; the TTM figure through Jun 2026 stood at 0.03 (up 124.67% YoY), while the FY2025 annual figure was 0.03, changed N/A from the prior year.
- Asset Utilization Ratio came in at 0.03 for Q2 2026 at BioAge Labs, down from 0.03 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.03 in Q4 2025 to a low of 0.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 0.33 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 0.54 |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | 0.03 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.03 |
| Mar 31, 2026 | 0.03 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.00 |